Xeris Pharmaceuticals, Inc. (XERS) financial statements (2021 and earlier)

Company profile

Business Address 180 NORTH LASALLE STREET
CHICAGO, IL 60601
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13476113
Cash and cash equivalents382046
Short-term investments965667
Receivables753
Inventory, net of allowances, customer advances and progress billings82 
Inventory82 
Prepaid expense342
Other undisclosed current assets 1 
Total current assets:15287118
Noncurrent Assets
Property, plant and equipment782
Long-term investments and receivables 13 
Long-term investments 13 
Regulated entity, other noncurrent assets(4)  
Other noncurrent assets000
Other undisclosed noncurrent assets4  
Total noncurrent assets:7222
TOTAL ASSETS:159109120
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19249
Accounts payable361
Accrued liabilities16188
Other liabilities00 
Other undisclosed current liabilities931
Total current liabilities:282710
Noncurrent Liabilities
Liabilities, other than long-term debt, including:493
Deferred rent credit7  
Other undisclosed liabilities, other than long-term debt(3)93
Other undisclosed noncurrent liabilities945832
Total noncurrent liabilities:976734
Total liabilities:1259545
Stockholders' equity
Stockholders' equity attributable to parent341475
Common stock000
Additional paid in capital371261196
Accumulated other comprehensive income (loss)00(0)
Accumulated deficit(337)(246)(121)
Total stockholders' equity:341475
TOTAL LIABILITIES AND EQUITY:159109120

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Revenues2020
Cost of revenue(9)(2)(0)
Cost of goods and services sold(9)(2) 
Other undisclosed gross profit012
Gross profit:1112
Operating expenses(95)(123)(62)
Operating loss:(84)(122)(59)
Nonoperating expense
(Other Nonoperating expense)
(8)(4)(1)
Interest and debt expense023
Loss from continuing operations before income taxes:(91)(124)(58)
Income tax benefit000
Net loss:(91)(123)(57)
Other undisclosed net loss attributable to parent(0)(2)(3)
Net loss available to common stockholders, diluted:(91)(126)(60)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(91)(123)(57)
Other comprehensive loss(91)(125)(60)
Comprehensive loss:(182)(249)(118)
Other undisclosed comprehensive income, net of tax, attributable to parent182249 
Comprehensive income (loss), net of tax, attributable to parent:(0)0(118)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: